Evidence map›Paper›PMID 29512604›Full record

ArticleThe Indian journal of medical research2017

Pooja Agarwal, A R Anvikar, C R Pillai, Kumkum Srivastava

Open access · diamondAbstract read
In one paragraph

Article in The Indian journal of medical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. TheScience advances · 2026
    Article
  2. A propidium iodide-basedAntimicrobial agents and chemotherapy · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Pooja AgarwalDivision of Parasitology, CSIR-Central Drug Research Institute, Lucknow; Academy of Scientific & Innovative Research, New Delhi, India.
A R AnvikarICMR-National Institute of Malaria Research, New Delhi, India.
C R PillaiICMR-National Institute of Malaria Research, New Delhi, India.
Kumkum SrivastavaDivision of Parasitology, CSIR-Central Drug Research Institute, Lucknow; Academy of Scientific & Innovative Research, New Delhi, India.
National Institute of Malaria Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & objectives: : The in vitro assays for susceptibility of Plasmodium falciparum to antimalarial drugs are important tools for monitoring drug resistance. During the present study, efforts were made to establish long-term continuous in vitro culture of Indian field isolates of P. falciparum and to determine their sensitivity to standard antimalarial drugs and antibiotics. Methods: Four (MZR-I, -II, -III and -IV) P. falciparum isolates were obtained from four patients who showed artemisinin-based combination therapy (ACT) from Mizoram, a north-eastern State of India, and characterized for their in vitro susceptibility to chloroquine diphosphate (CQ), quinine hydrochloride dehydrate, mefloquine, piperaquine, artemether, arteether, dihydro-artemisinin (DHA), lumefantrine and atovaquone and antibiotics, azithromycin and doxycycline. These patients showed ACT treatment failure. Two-fold serial dilutions of each drug were tested and the effect was evaluated using the malaria SYBR Green I fluorescence assay. K1 (chloroquine-resistant) and 3D7 (chloroquine-sensitive) reference strains were used as controls. Results: Growth profile of all field isolates was identical to that of reference parasites. The IC50 values of all the drugs were also similar against field isolates and reference parasite strains, except K1, exhibited high IC50 value (275±12.5 nM) of CQ for which it was resistant. All field isolates exhibited higher IC50 values of CQ, quinine hydrochloride dihydrate and DHA compared to reference strains. The resistance index of field isolates with respect to 3D7 ranged between 260.55 and 403.78 to CQ, 39.83 and 46.42 to quinine, and 2.98 and 4.16 to DHA, and with respect to K1 strain ranged between 6.51 and 10.08, 39.26 and 45.75, and 2.65 and 3.71. MZR-I isolate exhibited highest resistance index. Interpretation & conclusions: As the increase in IC50 and IC90 values of DHA against field isolates of P. falciparum was not significant, the tolerance to DHA-piperaquine (PPQ) combination might be because of PPQ only. Further study is required on more number of such isolates to generate data for a meaningful conclusion.

Indexed as

Anti-Bacterial AgentsAntimalarialsArtemetherArtemisininsAtovaquoneAzithromycinChloroquineDoxycyclineEthanolaminesFluorenesHumansIndiaLumefantrineMalaria, FalciparumMefloquinePiperazinesAnti-Bacterial AgentsAntimalarialsArtemetherArtemisininsartemotilAtovaquoneAzithromycinChloroquinechloroquine diphosphateDoxycyclineEthanolaminesFluorenesLumefantrineMefloquinepiperaquinePiperazinesQuinineQuinolinesAntibiotics - antimalarials - field isolates - in vitro culture - Mizoram - Plasmodium falciparum

Identifiers

PMID29512604
PMCPMC5861473
OpenAlexW2800274217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.